Amicus touts latest set of gene therapy data; Novo Nordisk expands discovery deal for diabetes
→ The execs at Amicus Therapeutics $FOLD spared no effort in touting an early set of data for their gene therapy program to treat CLN6 Batten disease. At the interim, the snapshot results showed little change in 8 patients treated up to 24 months ago. The biotech says that they would normally have experienced a decline, given historical results for the disease. The stock, though, barely budged on the update Thursday morning.
→ Novo Nordisk is expanding their discovery pact with Oxford-based e-Therapeutics, adding the biotech’s new genomics tech in the hunt for new Type 2 diabetes drugs. “In addition to extending the original contract, this marks the first deal on our new “GAINs” functional genomics technology in a hugely important disease area,” noted e-Therapeutics CEO Ray Barlow.
→ Exelixis has announced plans to front a new collaboration deal with India’s Aurigene Discovery Technologies with $10 million upfront, looking for new cancer drugs. Aurigene is focused on oncology and inflammatory disorders. They’ll go after 3 different programs which each have a $2.5 million option price.
→ Clovis Oncology managed to disappoint Wall Street again today, reporting $33 million in Rubraca revenue for Q2— below the consensus. The stock quickly slid 15% as their PARP continues to struggle, with AstraZeneca’s Lynparza well in the lead.